CL2018000609A1 - Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue. - Google Patents

Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue.

Info

Publication number
CL2018000609A1
CL2018000609A1 CL2018000609A CL2018000609A CL2018000609A1 CL 2018000609 A1 CL2018000609 A1 CL 2018000609A1 CL 2018000609 A CL2018000609 A CL 2018000609A CL 2018000609 A CL2018000609 A CL 2018000609A CL 2018000609 A1 CL2018000609 A1 CL 2018000609A1
Authority
CL
Chile
Prior art keywords
vaccine against
preparing
dengue virus
against dengue
tetravalent vaccine
Prior art date
Application number
CL2018000609A
Other languages
English (en)
Inventor
Neuza Maria Frazatti Gallina
Original Assignee
Fund Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Butantan filed Critical Fund Butantan
Publication of CL2018000609A1 publication Critical patent/CL2018000609A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

PROCESO PARA PREPARAR UNA VACUNA TETRAVALENTE ATENUADA CONTRA EL VIRUS DEL DENGUE Y PRODUCTO DEL MISMO. LA PRESENTE INVENCIÓN TAMBIÉN SE REFIERE A UN PROCESO DE PREPARACIÓN DE UNA VACUNA TETRAVALENTE CONTRA EL DENGUE PARA SU ADMINISTRACIÓN A UN SUJETO, A UN MÉTODO PARA INDUCIR UNA RESPUESTA INMUNE CONTRA LOS SEROTIPOS 1, 2, 3 Y 4 DEL VIRUS DEL DENGUE EN UN PACIENTE Y A UN CONJUNTO DE ELEMENTOS DE UNA VACUNA TETRAVALENTE CONTRA EL DENGUE.
CL2018000609A 2015-09-08 2018-03-08 Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue. CL2018000609A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/847,422 US10004795B2 (en) 2015-09-08 2015-09-08 Process for preparing an attenuated tetravalent dengue vaccine

Publications (1)

Publication Number Publication Date
CL2018000609A1 true CL2018000609A1 (es) 2018-08-17

Family

ID=56268413

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000609A CL2018000609A1 (es) 2015-09-08 2018-03-08 Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue.

Country Status (17)

Country Link
US (2) US10004795B2 (es)
EP (1) EP3347043A1 (es)
JP (1) JP6968070B2 (es)
CN (1) CN108289945B (es)
AR (1) AR105966A1 (es)
AU (1) AU2016318349B2 (es)
BR (1) BR102015030332B1 (es)
CL (1) CL2018000609A1 (es)
CO (1) CO2018003451A2 (es)
CR (1) CR20180202A (es)
CU (1) CU24579B1 (es)
EC (1) ECSP18026090A (es)
HK (1) HK1258584A1 (es)
MX (2) MX2018002901A (es)
PE (1) PE20181135A1 (es)
TW (1) TWI733694B (es)
WO (1) WO2017041156A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211814A1 (es) 2013-03-15 2021-09-14 Takeda Vaccines Inc Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
CU24701B1 (es) 2017-10-16 2024-04-08 Serum Institute Of India Pvt Ltd Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparación de las mismas
SG11202005251VA (en) 2017-12-07 2020-07-29 Merck Sharp & Dohme Formulations of dengue virus vaccine compositions
MX2021002586A (es) 2018-09-05 2021-06-08 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administracion de esta.
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
WO2023044774A1 (en) * 2021-09-24 2023-03-30 Sichuan Clover Biopharmaceuticals, Inc. Tpo mimetic fusion proteins and methods of use submission of sequence listing as ascii text file

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60334310D1 (de) * 2002-05-03 2010-11-04 Us Gov Health & Human Serv Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
GB0304799D0 (en) * 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
DK1694828T3 (da) * 2003-12-19 2011-05-23 Wyeth Llc Fremgangsmåde til fremstilling af serum-fri vero-celle-bank
WO2006066332A1 (en) * 2004-12-23 2006-06-29 Murray Goulburn Co-Operative Co Limited Method of manufacture of a modified milk powder suitable as a rennet casein extender or replacer
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
PE20211814A1 (es) * 2013-03-15 2021-09-14 Takeda Vaccines Inc Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas
WO2015048744A2 (en) * 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine

Also Published As

Publication number Publication date
WO2017041156A1 (en) 2017-03-16
MX2018002901A (es) 2018-09-18
AU2016318349A1 (en) 2018-04-19
US20180256702A1 (en) 2018-09-13
CN108289945B (zh) 2022-05-31
JP2018527408A (ja) 2018-09-20
AR105966A1 (es) 2017-11-29
EP3347043A1 (en) 2018-07-18
PE20181135A1 (es) 2018-07-17
CU20180025A7 (es) 2018-11-06
MX2021013109A (es) 2021-11-17
CU24579B1 (es) 2022-02-04
BR102015030332A2 (pt) 2016-07-05
US10201600B2 (en) 2019-02-12
CO2018003451A2 (es) 2018-11-30
BR102015030332B1 (pt) 2019-11-05
CR20180202A (es) 2018-08-10
HK1258584A1 (zh) 2019-11-15
ECSP18026090A (es) 2018-10-31
TW201718008A (zh) 2017-06-01
CN108289945A (zh) 2018-07-17
JP6968070B2 (ja) 2021-11-17
AU2016318349B2 (en) 2019-10-17
US20170065701A1 (en) 2017-03-09
US10004795B2 (en) 2018-06-26
TWI733694B (zh) 2021-07-21

Similar Documents

Publication Publication Date Title
CL2018000609A1 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue.
PH12018500127A1 (en) Vaccine compositions
MX2018007627A (es) Vacuna contra el virus del zika.
MX2018005569A (es) Vacunas contra el virus de la hepatitis b.
ECSP18001613A (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
EP3127552A4 (en) Microneedle array preparation comprising inactivated whole virus vaccine and method for administering same
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
SG11201706342PA (en) An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
ECSP17021465A (es) Formulación que comprende glicopirrolato, método y aparato
IL259451A (en) Live virus with accumulation of dengue fever of a weakened nature and vaccination of dengue fever containing identical antigens
PL406972A1 (pl) Sposób otrzymywania kompozycji zawierającej klotrimazol oraz kompozycja farmaceutyczna uzyskana tym sposobem
TH1501003876A (th) วัคซีนของไทรเมอร์ของถุงหุ้ม (Env) ของไวรัสโรคภูมิคุ้มกันบกพร่องของ มนุษย์ซึ่งทำให้เกิดเสถียรภาพ (HIV) และวิธีการของการใช้ที่เหมือนกัน